Posterior reversible encephalopathy syndrome (PRES) and myeloma

被引：1

作者：

Ghanem, Ricardos ^{[1
]}

Glaisner, Sylvie ^{[2
]}

Bobin, Arthur ^{[3
]}

Cereja, Sophie ^{[1
]}

Joly, Bertrand ^{[1
]}

Salanoubat, Celia ^{[1
]}

Fouquet, Guillemette ^{[1
,4
]}

机构：

[1] Ctr Hosp Sud Francilien, Hematol Clin, Corbeil Essonnes, France

[2] Inst Curie, Dept Oncol Med, Paris, France

[3] CHU Poitiers, Serv Hematol & Therapie Cellulaire, Pole Reg Cancerol, Poitiers, France

[4] Univ Paris, Inst Cochin, INSERM U1016, CNRS,UMR8104,Fac Med Cochin Port Royal, Paris, France

来源：

LEUKEMIA RESEARCH REPORTS | 2024年 / 21卷

关键词：

Myeloma; Neurotoxicity; Cerebrovascular complication; Posterior reversible encephalopathy syndrome; Chemotherapy; MULTIPLE-MYELOMA; PATIENT; CARFILZOMIB;

D O I：

10.1016/j.lrr.2023.100407

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Posterior reversible encephalopathy syndrome (PRES) has rarely been described in myeloma, but chemotherapy is a known risk factor. We report 3 patients with myeloma who developed PRES, and analyzed them with 13 published cases, mostly women. The most frequent causative agents were proteasome inhibitors and autologous stem cell transplantation. Risk factors were frequently associated: hypertension, infection or renal failure. Symptoms included headache, blurred vision, altered mental status, seizures. Most patients experienced rapid clinical recovery, without relapse even after resuming treatment. Although rare, we must remain vigilant about PRES in myeloma patients. Stricter control of blood pressure could limit its occurrence.

引用

页数：4

共 15 条

[1] Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma [J].

Cai, Xuemei ;

Bhattacharyya, Shamik ;

Plitt, Anna ;

Raibagkar, Pooja ;

LaBuzetta, Jamie N. ;

Schleicher, Stephen M. ;

Munshi, Nikhil C. ;

Klein, Joshua P. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02) :E1-E5

[2] Posterior reversible encephalopathy syndrome in a patient with multiple myeloma treated with thalidomide [J].

Chow, Signy ;

Cheung, Christina S. ;

Lee, Donald H. ;

Howson-Jan, Kang ;

Xenocostas, Anargyros .

LEUKEMIA & LYMPHOMA, 2012, 53 (05) :1003-1005

[3]

ehealthme, 2023, ABOUT US

[4] Posterior reversible encephalopathy syndrome [J].

Fischer, Marlene ;

Schmutzhard, Erich .

JOURNAL OF NEUROLOGY, 2017, 264 (08) :1608-1616

[5] Bortezomib-induced Posterior Reversible Encephalopathy Syndrome: Clinical and Imaging Features [J].

Ho, Chien-Hui ;

Lo, Chung-Ping ;

Tu, Min-Chien .

INTERNAL MEDICINE, 2014, 53 (16) :1853-1857

[6]

Kadhem S, 2017, CUREUS J MED SCIENCE, V9, DOI 10.7759/cureus.1041

[7]

Kager L.M., 2009, BMJ Case Rep, V2009

[8] Carfilzomib: a rare cause of posterior reversible encephalopathy syndrome [J].

Katz-Agranov, Nurit ;

Padilla, Jennifer ;

Scoon, Joanna ;

Cherian, Sujith V. .

ANNALS OF HEMATOLOGY, 2016, 95 (11) :1923-1924

[9]

Kelly Kevin, 2008, Br J Haematol, V141, P566, DOI 10.1111/j.1365-2141.2008.07088.x

[10]

Nixon N.A., 2014, BMJ Case Rep, V2014

← 1 2 →